UNSPSC 51332518: Haloperidol decanoate

This classification denotes a butyrophenone with the molecular formula C31H41ClFNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AC20PJ4101, chemically known as 1-butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)- but more generally known as haloperidol decanoate, which bears US NIH Compound Identifier 3559. European Medicines Agency schedules Haloperidol decanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02452MIG.

UNSPSC 51332518 Haloperidol decanoate is a Commodity code that nominally covers a specific antipsychotic pharmaceutical product, but recent state and local procurement activity under this code does not reflect haloperidol decanoate purchases. Instead, the code appears to be receiving misclassified submissions spanning broader pharmaceutical procurement — including naloxone (an opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and therapeutic pharmacy initiatives. State and local issuing bodies using this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The scope of actual work solicited under this code encompasses pharmaceutical supply chain contracting, drug procurement and distribution logistics, pharmacy benefit management coordination, and manufacturer-to-government direct contracting arrangements.

Geographic activity is concentrated in Florida, Texas, and Minnesota, with the code also serving participating states within cooperative purchasing frameworks such as Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; Texas HHS Commission's Request for Information HHS0017013 (posted April 3, 2026) soliciting vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities. The mismatch between the code's nominal scope and actual procurement activity signals that this code classification is not reliably aligned with haloperidol decanoate or similar single-entity pharmaceutical products in current state and local sourcing practice.